在急性缺血性中风中使用尿素酶进行静脉内血栓溶解
Yue Qiao1, Jing Wang1, Thanh Nguyen2
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Brain sciences
|October 25, 2024
概括
泌尿酸酶是一种具有成本效益的急性缺血性中风 (AIS) 血栓缓解药物,在新药无法获得时提供可行的治疗选择. 需要进一步的研究来证实它的疗效与较新的药物相比.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉内血栓溶解是急性缺血性中风 (AIS) 的关键治疗方法.
- 泌尿酸酶提供了一个具有成本效益的血栓溶解药物选择,特别是在资源有限的环境中,与阿尔特和特内克相比.
研究的目的:
- 审查尿素激酶对AIS的临床应用.
- 为了评估尿素酶的疗效,安全性和成本效益,与其他血栓解毒剂相比.
主要方法:
- 关于使用尿素激酶对AIS进行静脉内血栓溶解的综合文献综述.
- 尿素激酶与阿尔特和特内克相比的比较分析.
主要成果:
- 泌尿酸酶是一种第一代血栓缓解剂,是一种非特异性等离子体激活剂,已使用20多年.
- 它改善了AIS患者在中风后6小时内接受治疗的神经结果.
- 由于成本,时间或可用性限制,尿素酶是一种可行的替代方案.
结论:
- 泌尿酸酶是低收入和中等收入国家AIS的成本有效的血栓溶解剂.
- 需要高层次的证据来确认尿素酶的非劣势性,或潜在的优势性,以较新的血栓抑制剂.
相关概念视频
Venous Thrombosis III: Interprofessional Care
2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
Clot Retraction and Fibrinolysis
4.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.4K
Acute Coronary SyndromeI: Introduction
3
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3


